PERSEUS - A Prospective Non-interventional Study to Assess the Effectiveness of Aflibercept (Eylea) in Routine Clinical Practice in Patients With Wet Age-related Macular Degeneration
Phase of Trial: Phase IV
Latest Information Update: 02 Apr 2018
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PERSEUS
- Sponsors Bayer
- 16 Jun 2017 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 30 Jun 2017.
- 17 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov